Autolus Therapeutics plc Quarterly Nonoperating Income (Expense) in USD from Q4 2017 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
Summary
Autolus Therapeutics plc quarterly/annual Nonoperating Income (Expense) history and growth rate from Q4 2017 to Q2 2024.
  • Autolus Therapeutics plc Nonoperating Income (Expense) for the quarter ending June 30, 2024 was $708K.
  • Autolus Therapeutics plc Nonoperating Income (Expense) for the twelve months ending June 30, 2024 was -$40.1M, a 1230% decline year-over-year.
  • Autolus Therapeutics plc annual Nonoperating Income (Expense) for 2023 was -$28.7M, a 456% decline from 2022.
  • Autolus Therapeutics plc annual Nonoperating Income (Expense) for 2022 was -$5.16M, a 422% decline from 2021.
  • Autolus Therapeutics plc annual Nonoperating Income (Expense) for 2021 was -$988K, a 152% decline from 2020.
Nonoperating Income (Expense), Trailing 12 Months (USD)
Nonoperating Income (Expense), Quarterly (USD)
Nonoperating Income (Expense), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 -$40.1M $708K +$1.84M Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-08
Q1 2024 -$42M -$13.9M -$13.3M -1959% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-17
Q4 2023 -$28.7M -$23.9M -$28.1M -667% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-21
Q3 2023 -$557K -$2.97M +$2.46M +45.3% Jul 1, 2023 Sep 30, 2023 10-K 2024-03-21
Q2 2023 -$3.02M -$1.14M +$1.92M +62.8% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-08
Q1 2023 -$4.93M -$677K +$225K +24.9% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-17
Q4 2022 -$5.16M $4.22M Oct 1, 2022 Dec 31, 2022 10-K 2024-03-21
Q3 2022 -$5.43M Jul 1, 2022 Sep 30, 2022 10-K 2024-03-21
Q2 2022 -$3.05M Apr 1, 2022 Jun 30, 2022 10-K 2024-03-21
Q1 2022 -$902K -$1.78M -202% Jan 1, 2022 Mar 31, 2022 10-K 2024-03-21
Q1 2021 -$2.22M $882K -$4.11M -82.3% Jan 1, 2021 Mar 31, 2021 6-K 2021-05-06
Q4 2020 $1.89M -$1.11M +$614K +35.6% Oct 1, 2020 Dec 31, 2020 20-F 2023-03-07
Q3 2020 $1.27M -$2.47M -$6.24M -166% Jul 1, 2020 Sep 30, 2020 6-K 2020-11-05
Q2 2020 $7.52M $478K -$4.98M -91.2% Apr 1, 2020 Jun 30, 2020 6-K 2020-08-06
Q1 2020 $12.5M $4.99M +$5.44M Jan 1, 2020 Mar 31, 2020 6-K 2021-05-06
Q4 2019 $7.06M -$1.73M -$3.48M -198% Oct 1, 2019 Dec 31, 2019 20-F 2022-03-10
Q3 2019 $10.5M $3.77M +$1.77M +88.4% Jul 1, 2019 Sep 30, 2019 6-K 2020-11-05
Q2 2019 $8.77M $5.45M -$1.2M -18.1% Apr 1, 2019 Jun 30, 2019 6-K 2020-08-06
Q1 2019 $9.97M -$443K Jan 1, 2019 Mar 31, 2019 6-K 2020-05-07
Q4 2018 $1.76M +$2.26M Oct 1, 2018 Dec 31, 2018 20-F 2021-03-04
Q3 2018 $2M Jul 1, 2018 Sep 30, 2018 6-K 2019-11-07
Q2 2018 $6.66M Apr 1, 2018 Jun 30, 2018 6-K 2019-08-08
Q4 2017 -$504K Oct 1, 2017 Dec 31, 2017 20-F 2019-02-25
* An asterisk sign (*) next to the value indicates that the value is likely invalid.